Sanofi Total Liabilities 2012-2026 | SNY
Sanofi total liabilities from 2012 to 2026. Total liabilities can be defined as the total value of all possible claims against the corporation.
- Sanofi total liabilities for the quarter ending June 30, 2026 were $69.173B, a 11.44% increase year-over-year.
- Sanofi total liabilities for 2025 were $62.334B, a 4.85% increase from 2024.
- Sanofi total liabilities for 2024 were $59.452B, a 5.41% increase from 2023.
- Sanofi total liabilities for 2023 were $56.4B, a 3.8% increase from 2022.
|
Sanofi Annual Total Liabilities (Millions of US $) |
|
|---|---|
| 2025 | $62,334 |
| 2024 | $59,452 |
| 2023 | $56,400 |
| 2022 | $54,334 |
| 2021 | $60,588 |
| 2020 | $58,694 |
| 2019 | $60,063 |
| 2018 | $61,853 |
| 2017 | $46,984 |
| 2016 | $51,953 |
| 2015 | $48,981 |
| 2014 | $54,666 |
| 2013 | $51,871 |
| 2012 | $55,219 |
| 2011 | $60,971 |
|
Sanofi Quarterly Total Liabilities (Millions of US $) |
|
|---|---|
| 2026-06-30 | $69,173 |
| 2026-03-31 | $64,233 |
| 2025-12-31 | $62,334 |
| 2025-09-30 | $65,763 |
| 2025-06-30 | $62,073 |
| 2025-03-31 | $60,549 |
| 2024-12-31 | $59,452 |
| 2024-06-30 | $61,123 |
| 2023-12-31 | $56,400 |
| 2023-06-30 | $57,144 |
| 2022-12-31 | $54,334 |
| 2022-06-30 | $53,766 |
| 2021-06-30 | $58,988 |
| 2017-12-31 | $46,984 |
| 2017-06-30 | $48,495 |
| 2016-12-31 | $51,953 |
| 2016-06-30 | $50,568 |
| 2015-06-30 | $45,519 |
| 2014-06-30 | $53,436 |
| 2013-06-30 | $53,270 |
| 2012-06-30 | $58,329 |
| 2012-03-31 | $0 |
| 2011-12-31 | $60,971 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $104.590B | $49.347B |
| Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $1084.858B | 36.60 |
| Johnson & Johnson (JNJ) | United States | $651.203B | 24.88 |
| AbbVie (ABBV) | United States | $466.469B | 24.29 |
| Merck (MRK) | United States | $363.044B | 45.84 |
| Roche Holding AG (RHHBY) | Switzerland | $348.022B | 0.00 |
| Novartis AG (NVS) | Switzerland | $268.897B | 16.24 |
| Novo Nordisk (NVO) | Denmark | $192.843B | 10.74 |
| Pfizer (PFE) | United States | $157.539B | 9.06 |
| Bayer (BAYRY) | Germany | $55.531B | 9.88 |
| Innoviva (INVA) | United States | $1.521B | 5.20 |